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Background: DNA methylation mediates gene silencing primarily by inducing repressive chromatin architecture via
a common theme of interaction involving methyl-CpG binding (MBD) proteins, histone modifying enzymes and
chromatin remodelling complexes. Hence, targeted inhibition of MBD protein function is now considered a potential
therapeutic alternative for thwarting DNA hypermethylation prompted neoplastic progress. We have analyzed the gene
and protein expression level of the principal factors responsible for gene silencing, that is, DNMT and MBD proteins in
MCF-7 and MDA-MB-231 breast cancer cell lines after treatment with various epigenetic drugs.
Results: Our study reveals that the epigenetic modulators affect the expression levels at both transcript and protein
levels as well as encourage growth arrest and apoptosis in MCF-7 and MDA-MB-231 cells. AZA, TSA, SFN, and
SAM inhibit cell growth in MCF-7 and MDA-MB-231 cell lines in a dose-dependent manner, that is, with increasing
concentrations of drugs the cell viability gradually decreases. All the epigenetic modulators promote apoptotic
cell death, as is evident form increased chromatin condensation which is a distinct characteristic of apoptotic
cells. From FACS analysis, it is also clear that these drugs induce G2-M arrest and apoptosis in breast cancer cells.
Further, transcript and protein level expression of MBDs and DNMTs is also affected - after treatment with epigenetic
drugs; the level of transcripts/mRNA of MBDs and DNMTs has consistently increased in general. The increase in level of
gene expression is substantiated at the protein level also where treated cells show higher expression of DNMT1,
DNMT3A, DNMT3B, and MBD proteins in comparison to untreated cells. In case of tissue samples, the expression
of different DNMTs is tissue stage-specific. DNMT1 exhibits significantly higher expression in the metastatic stage,
whereas, DNMT3A and DNMT3B have higher expression in the primary stage in comparison to the metastatic samples.
Conclusion: The epigenetic modulators AZA, TSA, SFN, and SAM may provide opportunities for cancer prevention by
regulating the components of epigenetic gene-silencing machinery especially DNMTs and MBDs.
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DNA methylation is one of the principal epigenetic en-
forcers participating in cell-specific regulation of tran-
scriptional activity. DNA methylation basically acts as a
gene-silencing mechanism to turn off specific genes and
bring about functional re-orientation of the genomic data
at crucial junctures during development and differenti-
ation [1,2]. Methylation of DNA is a post-synthetic process* Correspondence: samirp@nitrkl.ac.in
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unless otherwise stated.catalyzed by a family of dedicated enzymes known as DNA
Methyltransferases (DNMTs). DNMT1, DNMT3A, and
DNMT3B methylate the C5 of cytosine residue specifically
at CpG rich promoter sequences in the presence of cofactor
S-Adenosyl methionine (SAM) which donates the -CH3
group and is converted to S-Adenosyl homocysteine (SAH)
[3,4]. DNA methylation plays an important role in main-
tenance of genome integrity (by silencing of repetitive se-
quences, endogenous retroviruses, selfish genetic elements
like transposons) and contributes significantly towards X-
chromosome inactivation, tissue-specific gene expression,
and induction of stem cell differentiation [5-8].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lation is implicated in gene silencing, the exact mechanism
via which this epigenetic tag is co-related with transcrip-
tional inactivation remained a topic of intense speculation.
It was assumed that methylated cytosines sterically hinder
the binding of transcription factors and RNA polymerase II
to their cognate recognition sequences. Also, methylation
of DNA resulting in nucleosomal repositioning and high-
order chromatin remodeling leads to formation of inactive
heterochromatin compartments which further obstructs
the gene expression circuit [9,10]. However, a strong con-
nection between DNA methylation and subsequent gene
silencing was confirmed after the discovery of a family
of conserved proteins, the methyl-CpG-binding domain
(MBD) proteins [11-14]. The MBD protein family com-
prises of five prominent nuclear proteins MeCP2, MBD1,
MBD2, MBD3, and MBD4 who are tagged as the epi-
genetic readers of the methyl signature propagated by the
DNMTs [15]. MBD proteins interact with the DNA around
the methylated cytosine bases to maintain or alter nucleo-
somal architecture and direct gene-expression programs.
In addition to denying access to the regulators of the tran-
scriptional machinery, MBD proteins also recruit histone
deacetylases (HDACs) and chromatin remodeling com-
plexes such as NuRD, SWI/SNF, and Mi-2 to methyl-
CpG-enriched promoters in the genome to modulate the
chromatin structure and repress transcription [16-19].
DNA methylation patterns are profoundly altered in
malignant cells, characterized by paradoxical gene-specific
regional hypermethylation and global hypomethylation of
the genome [20,21]. While global genomic demethylation
is mainly responsible for oncogene activation and chromo-
somal instability, DNA methylation arbitrated promoter
CpG island hypermethylation leads to silencing and inacti-
vation of tumor suppressor genes, thus paving the way for
neoplastic transformation [22-24]. The hypermethylation-
induced silencing of tumor suppressor genes in cancer
cells is mediated by MBD proteins which bind to the
methylated promoters, preventing their transcriptional
activation in time to stop cancer [25-31]. MBD protein
occupancy of hypermethylated promoters of tumor sup-
pressor genes, cell cycle regulatory, and DNA repair genes
followed by their silencing has been reported in a number
of cancers (Figure 1). These observations have corrobo-
rated the hypothesis that MBD proteins act as the conduit
that links DNA hypermethylation and transcriptional mis-
regulation with neoplasia. Therefore, targeted inhibition of
MBD proteins is now considered as a means of unmasking
silenced genes and initiating transcriptional activity in a
bid to counterattack malignant transformation [32].
In view of this, treatment with inhibitors of DNA methy-
lation and histone deacetylation can reactivate epige-
netically silenced tumor suppressor genes and successively
restore normal gene function such as induction of growtharrest and apoptosis in cancer cells [33]. In this study, we
have analyzed the gene and protein expression profile
of DNMT and MBD proteins in two breast cancer cell
lines after treatment with various epigenetic drugs such
as DNMT and HDAC inhibitors- 5-Aza-2'-deoxycytidine
(AZA), Trichostatin A (TSA) and Sulforaphane (SFN), re-
spectively, and modulator SAM. The present study is aimed
at investigating the molecular effects of these epigenetic
manipulators on the expression and activity of the DNA
methylation mediated gene-silencing machinery as well as
on cell growth. The study will be useful in providing new
insights in regulation of DNMT and MBD function and
present new avenues for targeting their activity during
transcriptional inactivation and gene silencing. This study
will also establish DNA methylation and the crucial ele-
ments of epigenetic gene-silencing machinery as novel
targets for efficient therapeutic interventions in cancer
therapy.
Results
Epigenetic modulators inhibit cell growth in breast cancer
cell lines in a dose-dependent manner
The effect of four different epigenetic modulators (that
is, AZA, TSA, SFN, and SAM) on cell viability after 24 h
treatment was assessed by colorimetric MTT assay in
both the cell lines. The four modulators have their own
distinct effect on cell viability at different concentrations.
The cell survival level was observed to generally decrease
with an increase in drug concentration indicating a dose-
dependent behavior. An exception was seen in case of
SAM treated cells where cell viability did not exhibit a sig-
nificant decrease with regards to control untreated cells.
The IC50 value (that is, the concentration of drug which
results in 50% cell viability) were almost similar for both
the cell lines - 15, 10 μM, and 100 nM for AZA, SFN, and
TSA, respectively. A total of 15 μM of SAM was consid-
ered for treatment in both cell lines. Further experiments
were performed with the above-mentioned drug concen-
trations (Figure 2).
Expression profiles of DNMT and MBD genes after
treatment with epigenetic modulators
The effect of the epigenetic modulators on the expression of
DNMT and MBD was determined by the quantitative ana-
lysis of mRNA for each of them in two different cell lines. In
MCF-7, treatment with AZA resulted in an increase in ex-
pression of DNMT1 by 28.5-fold, of DNMT3A by 6.32-fold,
of DNMT3B by 8.65-fold, and by 11.3-fold, 6.3-fold, 8.5-fold,
11.2-fold, and 23.6-fold for MBD1, MBD2, MBD3, MBD4,
and MeCP2, respectively (Figure 3A). After treatment with
TSA, the level of gene expression of DNMT1, DNMT3A,
DNMT3B, MBD1, MBD2, MBD3, MBD4, and MECP2 in-
creases by 95.1-fold, 23.5-fold, 26.7-fold, 36.2-fold, 11.4-fold,
24.6-fold, 21.95-fold, and 48.3-fold, respectively, with regards
Figure 1 The figure represents the MBD protein family comprising of five prominent nuclear proteins MeCP2, MBD1, MBD2, MBD3,
and MBD4 and the protein partners they interact with such as histone deacetylases (HDACs) and chromatin remodeling complexes
such as NuRD, SWI/SNF, and Mi-2. The figure also depicts the various hypermethylated promoters to which the different MBD proteins bind
and mediate gene silencing in various cancer types. While MeCP2, MBD2, MBD3, and MBD4 interact with HDACs to bring about transcriptional
repression, MBD1 binds with DNMT1 and acts to silence the hypermethylated promoter regions. Thus, together DNMT and MBD proteins supervise
the epigenetic regulatory system to bring about transcriptional incompetence and lead to tumorigenic progression (Adapted from [26,28,29]).
Kar et al. Clinical Epigenetics 2014, 6:20 Page 3 of 13
http://www.clinicalepigeneticsjournal.com/content/6/1/20to untreated cells (Figure 3B). After treatment with SAM,
the mRNA level of DNMT1, DNMT3A, DNMT3B, MBD1,
MBD2, MBD3, MBD4, and MECP2 increases differently by
86-fold, 3.54-fold,19.4-fold, 23.6-fold, 46-fold,11.2-fold, 4.8-
fold, and 21.8-fold, respectively (Figure 3D). In case of
SFN treatment, there is an interesting observation. While
the level of DNMTs shows drastic decrease, MBD genes
are relatively highly expressed. There is downregulation of
DNMT1 by 0.75-fold, of DNMT3A by 0.0185-fold, and
DNMT3B by 1.174-fold. MBD1, MBD2, MBD3, MBD4,
and MeCP2 show an increase of 31.2-fold, 39.5-fold, 13.6-
fold, 36.8-fold, and 28.5-fold, respectively (Figure 3C).
In case of MDA-MB-231 cells, after treatment with AZA,
a known inhibitor of DNMTs, the transcript level of
DNMT1 increases by 22.1-fold, of DNMT3A by 4.19-fold,
and of DNMT3B by 9.69-fold, whereas there is an increase
in expression by 19.3-fold, 11.5-fold, 7.8-fold, 5.98-fold,
and 18.9-fold for MBD1, MBD2, MBD3, MBD4, and
MeCP2, respectively (Figure 3A). The transcript level ex-
pression of DNMTs and MBDs also increases after treat-
ment with TSA seen as 29-fold for DNMT1, 20.7-fold for
DNMT3A, 25-fold for DNMT3B, 28.4-fold for MBD1,
19.8-fold for MBD2, 14.6-fold for MBD3, 13.8-fold forMBD4, and 29.5-fold for MeCP2 (Figure 3B). However
after treatment with SFN, there is a difference between
the expression levels of DNMTs and MBDs just as in case
of MCF-7 cells. While the level of DNMTs is downregulated
by 0.196-fold for DNMT1, 0.00172-fold for DNMT3A, and
0.224-fold for DNMT3B, the expression of MBDs increases
by 33.9-fold for MBD1, 31.4-fold for MBD2, 18.7-fold
for MBD3, 19.4-fold for MBD4, and 29.1-fold for MeCP2
(Figure 3C). Additionally after treatment with SAM, both
the DNMT and MBD transcript levels show an increase
by 31-fold for DNMT1, 4.79-fold for DNMT3A, 17.4-fold
for DNMT3B, 27.5-fold for MBD1, 22-fold for MBD2,
10.2-fold for MBD3, 9.8-fold for MBD4, and 13.2-fold
for MeCP2 (Figure 3D). The most significant increase
in expression after AZA treatment is seen in DNMT1, in
MeCP2 after TSA treatment, in DNMT1 after treatment
with SAM, and in MBD1 after SFN treatment.
Epigenetic modulators promote apoptotic cell death in
breast cancer cells
Chromatin condensation analysis by Hoechst staining
was performed to study the cytotoxic effect of the epi-
genetic drugs on the MCF-7 and MDA-MB-231 cells
Figure 2 MTT assay to determine the IC50 value of the different drugs and analyze their effect on cell viability. The different drug
concentrations used and the corresponding cell viability graphs are shown for AZA (A), TSA (B), SFN (C), and SAM (D). The IC50 value (that is, the
concentration of drug which exhibited 50% cell viability for MCF-7 and MDA-MB-231 cells) were 15, 15, 10 μM, and 100 nM, respectively, for AZA,
SAM, SFN, and TSA, respectively.
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comes inert, highly condensed, undergoes fragmenta-
tion, and gets packaged into apoptotic bodies [34]. The
morphological changes induced by apoptosis can be de-
tected by the blue-fluorescent Hoechst 33342 dye which
brightly stains the highly condensed, dense chromatin of
apoptotic cells in comparison to the chromatin of non-
apoptotic cells. After treatment with the epigenetic modu-
lators at specific concentrations for 24 h - AZA (15 μM),
TSA (100 nM), SFN (10 μM), and SAM (15 μM), the per-
centage of condensed nuclei are found to be 38.45%, 70%,
65.36%, and 11.30%, respectively, with control cells exhibit-
ing 12.36% condensed nuclei in MC-7 cell line (Figure 4I).
In case of MDA-MB-231 cells, 43.18%, 59.26%, 60%, and
28.30% condensed nuclei are observed after AZA, TSA,
SFN, and SAM treatment, respectively, whereas the controlcells exhibit 6.94% condensed nuclei (Figure 4II). Therefore,
TSA and SFN are seen to be highly effective in inducing
apoptosis in breast cancer cells.
Higher protein expression corroborates the elevation in
transcript level expression of DNMT in breast cancer cells
Immunocytochemical analysis was performed to study
the effect of the epigenetic drugs and modulators on the
level of expression of DNMT proteins. It is observed
that in comparison to the untreated cells, the treated
cells show higher expression of DNMT1, DNMT3A,
DNMT3B, and MBD2 proteins which corroborates the
elevated level of mRNA expression of DNMT and MBD
proteins (Figure 5I and II). The other members of the
MBD family also exhibit similar upregulation as MBD2
as shown in Figure 5.
Figure 3 Relative expression analysis of the various drug treated cells at the transcript level. The effect of the epigenetic drugs - AZA
(A), TSA (B), SFN (C), and SAM (D) varied in different genes wherein the most significant increase in expression after AZA treatment was seen in
DNMT1, after TSA treatment in MeCP2, after treatment with SAM in DNMT1 and in MBD1 after SFN treatment.
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breast cancer
Similarly, the protein expression of DNMT proteins in FFPE
breast cancer tissue samples was studied by immunohisto-
chemistry. In all of the samples studied, there is signifi-
cant expression of DNMT proteins. The level of DNMT1
is higher in the metastatic stage tissue sample in compari-
son to the primary stage (Figure 6A and B). In contrast,
DNMT3A and DNMT3B show greater expression in the
primary tissues with regards to metastatic stage (Figure 6A
and B).
Epigenetic modulators induce G2-M arrest and apoptosis
in MCF-7 and MDA-MB-231 cells
In order to study the effect of the epigenetic drugs and
modulators on the cell cycle and cell growth, flow cytome-
try based cell cycle analysis after treatment with the epi-
genetic modulators was performed (Figure 7A). There is
an alteration in the cell cycle distributions in both MCF-7and MDA-MB-231 cells after treatment with various epi-
genetic factors for 24 h. When MCF-7 control (untreated)
cells were analyzed, percentage of G1, S, G2/M, and apop-
totic cells were found to be 58.5%, 12.3%, 14.6%, and
8.8%, respectively (Figure 7A(a)). After treatment with
AZA (15 μM), the percentage of G1, S, G2/M, and apop-
totic cells is found to be 36.3%, 6.0%, 6.5%, and 12.3%, re-
spectively (Figure 7B(a)). When cells were treated with
TSA, percentage of G1, S, G2/M, and apoptotic cells chan-
ged drastically to be 11.2%, 5.4%, 2.0%, and 25.9%, respect-
ively, with regards to untreated cells (Figure 7B(a)). Similar
changes are also observed after SFN treatment with 4.2%
cells in G1, 1.4% cells in S, 1.2% cells in G2, and 30.9% cells
in apoptotic phase. However, SAM treatment resulted in
45.7%, 4.7%, 6.9%, and 8.0% cells in G1, S, G2/M, and apop-
totic population, respectively.
In case of untreated MDA-MB-231 control cells, per-
centage of G1, S, G2/M, and apoptotic cells is 41.2%, 10.7%,
9.6%, and 8.5%, respectively (Figure 7B(b)). After treatment
Figure 4 MCF-7 and MDA-MB-231 cells were stained with Hoechst 33342 after treatment with AZA, TSA, SFN, and SAM for 24 h.
[I] The representative images of Hoechst 33342 stained nuclei and graphical representation of the percentage of condensed nuclei (n =3, mean ± S.D.)
for MCF-7 cells. [II] The representative images of Hoechst 33342 stained nuclei and graphical representation of the percentage of condensed nuclei
(n =3, mean ± S.D.) for MDA-MB-231 cells. P <0.05.
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apoptotic cells is found to be 41.1%, 5.1%, 6.4%, and 10.5%,
respectively (Figure 7B(b)). Similarly, for TSA (100 nM)
treatment, the percentage of G1, S, G2/M, and apoptotic
cells is observed to be 16.3%, 5.4%, 6.9%, and 23.3%, re-
spectively, with regards to untreated cells (Figure 7B(b)).
The percentage of G1, S, G2/M, and apoptotic cells
after treatment with SFN is seen to be 3.2%, 6.3%, 2.9%,
and 32.7%, respectively with regards to untreated cells
(Figure 7B(b)). Also, after SAM treatment, 47.6% of cells
in G1 phase, 9.6% of cells in S phase, 12.7% of cells in G2/
M, and 4.3% of apoptotic cells are reported with regards
to untreated cells (Figure 7B(b)). From the above results, it
is clear that SFN is most effective in inducing apoptosis in
both MCF-7 and MDA-MB-231 cells as is evident from
the highest percentage of apoptotic cells in case of SFN
treated cells with regards to untreated cells.
Discussion
The epigenetic gene-silencing machinery in the cell exe-
cutes its function via efficient co-ordination between the
two main protagonists - DNMT and MBD proteins. WhileDNA methylation ensures that the genes are effectively
tagged for inactivation, MBD proteins recognize these ‘OFF’
marks and result in chromatin compaction with the help
of histone modifying enzymes and chromatin remodel-
ing complexes. In recent years, epigenetic causes are being
considered as important hallmarks for malignant trans-
formation. In this context, targeted inhibition of DNMTand
MBD proteins is now considered as a means of unmasking
silenced genes to counterattack malignant transformation.
In the present study, we have analyzed the gene and
protein expression profile of DNMT and MBD proteins in
MCF-7 and MDA-MB-231 breast cancer cell lines after
treatment with known epigenetic modulators such as
DNMT inhibitor - AZA, Methyl donor - SAM, and HDAC
inhibitors - TSA and SFN. We have also investigated the
effect of these drugs on cell viability, cell cycle, and cell
growth in breast cancer cells. The epigenetic modulators
affect the cell growth of both the cell lines in a dose-
dependent manner, that is, with increasing concentrations
of drugs; the cell viability gradually decreases (Figure 2A,
B, C, and D). It can thus be assumed that epigenetic mod-
ulators may affect and modify the epigenetic modifications
Figure 5 Immunocytochemistry (40 X) of DNMT1, DNMT3A, DNMT3B, and MBD2. [I] Representative images of antibody bound proteins show
there is an increase in expression (arrow) after treatment with epigenetic modulators with respect to specific control (without treatment) cells in both
the cell lines. [II] Graphical representation of the expression level different DNMT and MBD proteins by relative intensity using ImageJ software.
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the cell viability of breast cancer cells.
We have observed that after treatment with epigenetic
drugs, the level of transcript expression of MBDs has
consistently increased for every drug treatment in boththe cell lines (Figure 3A, B, C, and D); however DNMTs
exhibit decrease in expression in comparison to untreated
cells after treatment with SFN (Figure 3C). The decrease
in DNMT expression after SFN treatment is consistent
with the results obtained by Hsu et al., in 2011, where they
Figure 6 Immunohistochemical analysis of the DNMT1, DNMT3A, and DNMT3B expression (20 X and 40 X magnifications). (A) DNMT1,
DNMT3A, and DNMT3B expression in primary breast cancer tissue samples. (B) DNMT1, DNMT3A, and DNMT3B expression in metastatic stage
FFPE tissues shows higher protein expression (arrow) in comparison to primary stage. DNMT1 shows relatively higher expression than DNMT3A
and DNMT3B in metastatic stage.
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and 3A mRNA expression and that SFN also impacts
global DNA methylation and site-specific demethylation
of the cyclin D2 promoter [35]. Keeping the above findings
in mind, it can be suggested that SFN has the ability to
affect DNA methylation either independently via a yet un-
known molecular mechanism or via association with his-
tone deacetylases by interrupting the MBD mediated
gene-silencing circuit.
The increase in level of gene expression is substantiated
at the protein level. The results of immunocytochemistry
demonstrate that epigenetic modulator treated cells show
higher expression of DNMT1, DNMT3A, DNMT3B, and
MBD proteins in comparison to untreated cells in both
the cell lines (Figure 5I and II). In case of tissue samples,
the expression of different DNMTs is tissue stage-specific.
DNMT1 exhibits significantly higher expression in the
metastatic stage, whereas DNMT3A and DNMT3B have
higher expression in the primary stage in comparison to
the metastatic samples (Figure 6A and B). This observation
may be indicative of the fact that DNMTs have differential
role to play during initiation, maintenance and progression
of neoplasia. It is already reported that DNMT3A andDNMT3B are de novo methyltransferases which mainly
add methyl groups to the cytosine bases of the newly
synthesized hemimethylated daughter strands at the replica-
tion foci [5,6]. Additionally, DNA hypermethylation-induced
gene silencing is a triggering event during tumorigenic
transformation [21,36,37]; hence DNMT3A and DNMT3B
are essentially required at this stage to methylate pro-
moter CpG islands adjacent to transcription start sites
of tumor-related genes, cell-cycle regulatory, and DNA
repair genes. Therefore, increased expression of DNMT3A
and DNMT3B in the primary stages rather than the meta-
static stage (Figure 6A and B) validates this information.
Although, many of the key gene-silencing events occur
very early during the premalignant stages of tumor pro-
gression, the process of epigenetic gene silencing con-
tinues through the entire progression of human cancer,
where DNMT1 plays the predominant role as the main-
tenance methyltransferase. Hence, the elevated level of
DNMT1 in the metastatic stage (Figure 6A and B) is a
confirmation of the above finding.
MBD proteins are known to interact with methylated
DNA in concert with HDACs to repress transcriptional
activity via heterochromatin formation. As the HDAC
Figure 7 FACS analysis of epigenetic modulator treated MCF-7 and MDA-MB-231 cells for 24 h to study the changes cell cycle distribution.
(A) AZA, TSA, SFN treatment shows G2/M phase arrest but TSA, SFN treatment were much more effective than AZA. (B) Graphical representation of G1,
S, G2/M, and APO population percentage in breast cancer cells (n =3, mean ± S.D.). P <0.05.
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ciate with MBD proteins, there is a possibility that the ac-
tion of MBD proteins can be disrupted. If the activity of
MBD proteins is disrupted, then DNMT mediated hyper-
methylation and gene silencing can also be effectively hin-
dered. Based on this assumption, MCF-7 and MDA-MB-
231 cells were treated with IC50 concentration of the epi-
genetic drugs - AZA (15 μM), TSA (100 nM), SFN
(10 μM), and SAM (15 μM) to study their effect on cell
cycle and cell growth. It is observed that all the epigenetic
modulators promote apoptotic cell death as is evident form
increased chromatin condensation which is a distinct char-
acteristic of apoptotic cells (Figure 4I and II). The percent-
age of condensed nuclei is highest in TSA and SFN treated
cells (Figure 4I and II), thus these two modulators are more
effective in inducing apoptotic cell death. On further ana-
lysis of the effect of these modulators on cell cycle, it is seen
that in comparison to control untreated cells, cells treated
with AZA and SAM, show increase in G1-phase cells, de-
creased percentage of S and G2 population as well as in-
crease in apoptotic cells (Figure 7A and B). Additionally,
cells treated with TSA and SFN exhibit reduction in G1
phase cells, decrease in percentage of G2 population and
drastic increase in apoptotic cell population (Figure 7A and
B). Thus, TSA and SFN affect all the stages of cell cycle, ar-
resting cell progression in each successive stage and ultim-
ately increasing the rate of apoptosis in the cell
population. From the above results, it is clear that the
epigenetic modulators - AZA, TSA, SFN, and SAM induce
differentiation, growth arrest, and apoptosis in breast
cancer cells.
The current work has significantly established that
epigenetic modulators such as DNMT and HDAC
inhibitors can indirectly affect the methylation mediated
gene-silencing machinery by directly targeting the
DNMTs and HDACs and thus affecting the expression of
DNMTs and MBDs. The findings of the study indicate
that the epigenetic modulators AZA, TSA, SFN, and SAM
affect the cell growth, viability, and apoptosis rate in breast
cancer cells. Previously, Mirza et al. had demonstrated
how natural polyphenols can modulate the expression of
DNMT proteins in breast cancer patients [38]. In lieu of
their analysis, we targeted both DNMTs and MBDs, the
crucial elements in the gene-silencing machinery via
epigenetic modulators. The current study for the first
time showcases a direct approach for targeting the gene-
silencing machinery during malignant transformation.
However, in-depth mechanistic studies should be carried
out to elucidate how these compounds affect the gene
transcription as the above drugs act at the protein level.
The study reinforces the view that these epigenetic
agents can induce cancer inhibitory activity and may
be useful in investigating epigenetic sources of cancer
treatment.Conclusions
As translational research in the field of cancer epigenomics
is increasingly focusing its attention towards achieving epi-
genetic therapies for cancer treatment, targeting the DNA
methylation-based gene-silencing machinery assumes great
significance. In this study, we have revealed the effect
of various epigenetic modulators on the gene and protein
level expression of DNMTs and MBD proteins. We have
also demonstrated how these modulators inhibit cell
growth, affect cell cycle by blocking G2-M progress and in-
duce apoptotic cell death. This study has demonstrated the
significance of targeting DNA methylation, histone modifi-
cation, especially, histone deacetylation and MBD proteins,
all of which concomitantly act to induce gene silencing
and transcriptional incompetence. The targeted inhibition
of MBD function via DNMT and HDAC inhibitors is thus
a promising therapeutic option for efficient treatment of
neoplastic progression.
Methods
In vitro cell culture and drug treatment
Human breast carcinoma cell lines MCF-7 and MDA-
MB-231 were obtained from ATCC through NCCS, Pune,
India. The cells were cultured and maintained in Modified
Eagle’s Medium (MEM) and Dulbecco’s Modified Eagle’s
Medium (DMEM), respectively, supplemented with 10%
(v/v) Fetal Bovine Serum (FBS) and 100 IU/mL Penicillin
and 0.1 mg/mL streptomycin in a humified atmosphere of
5% CO2 at 37°C. Stock solutions of AZA (Sigma), TSA
(Sigma), and SFN (Sigma) were prepared in dimethyl-
sulphoxide (DMSO) whereas SAM (Sigma) was dissolved
in milli-Q water. Stock solutions were further diluted to
working concentrations in DMEM prior to use. Cells were
harvested by trypsinization and cell number was counted
by hemocytometer. The number of living cells was calcu-
lated by Trypan blue staining (0.2% v/v). For determining
the concentration of drug that inhibited cell proliferation
by 50% (IC50), 5 X 10
3 cells per well were seeded in a 96-
well microtiter plates and after 24 h incubation, were
treated with the epigenetic modulators at different con-
centrations (AZA, SAM, SFN (1, 5, 10, 15, 20, 50 μM)
and TSA (10, 20, 50, 100, 250, 500 nM)) mixed in respect-
ive medias supplemented with 5% FBS. Control cells were
treated with DMSO only.
Cell viability analysis by colometric MTT assay
The effect of the epigenetic modulators, DNMT and
HDAC inhibitors on cellular proliferation was assessed
by 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium
Bromide (MTT) assay, using standard protocol. Briefly, the
drug-treated cells in each of the 96 wells were washed
twice with PBS. 0.8 mg/mL MTT solution was prepared
from stock MTT solution (5 mg/mL PBS, pH 7.2). A total
of 100 μL MTT solution was added to each well and
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moved and 100 μL of DMSO was added into each well to
dissolve the formazan crystals. The absorbance was mea-
sured at 570 nm and results were expressed as the mean of
three replicates as a percentage of control (taken as 100%).
The extent of cytotoxicity was defined as the relative re-
duction of the optical density (OD), which correlated to
the amount of viable cells in relation to cell control
(100%). The cell viability was plotted in a graph and the
IC50 was calculated accordingly to decide the optimum
dosage of the drugs for further studies.Relative gene expression analysis after drug treatment by
real-time PCR
MCF-7 and MDA-MB-231 cell lines were treated with
sub lethal dosages of AZA (15 μM), TSA (100 nM), SFN
(10 μM), and SAM (15 μM) for 24 h. After treatment for
the required time, total cellular RNA was extracted with
TriReagent (Sigma) according to the manufacturer’s in-
structions. qRT-PCR was performed using cDNA pre-
pared from 1 μg of total RNA prepared using RevertAid
First Strand cDNA Synthesis Kit (Thermo Scientific) and
SYBR® Green JumpStart™ Taq ReadyMix in the Realplex4-
Eppendorf system. The mRNA level was normalized to
β-actin, as described earlier [39]. The primer sequences
are provided in Table 1.Table 1 List of sequence and product length of the
real-time PCR primers used in this study
Gene Primer sequence Product
length (bp)
DNMT1 F 5′-GGCTGAGATGAGGCAAAAAG -3′ 112
R 5′-ACCAACTCGGTACAGGATGC -3′
DNMT3A F 5′-TATTGATGAGCGCACAAGAGAGC -3′ 111
R 5′-GGGTGTTCCAGGGTAACATTGAG -3′
DNMT3B F 5′-AATGTGAATCCAGCCAGGAAAGGC -3′ 191
R 5′-ACTGGATTACACTCCAGGAACCGT -3′
MeCP2 F 5′-TGACCGGGGACCCATGTAT -3′ 145
R 5′- CTCCACTTTAGAGCGAAAGGC -3′
MBD1 F 5′- CCTGGGTGCTGTGAGAACTGT -3′ 107
R 5′- TTGAAGGCAATTCTCTGTGCTC -3′
MBD2 F 5′- AGGTAGCAATGATGAGACCCTTTTA -3′ 116
R 5′- TAAGCCAAACAGCAGGGTTCTT -3′
MBD3 F 5′- CCGCTCTCCTTCAGTAAATGTAAC -3′ 101
R 5′- GGCTGGAGTTTGGTTTTCAGAA -3′
MBD4 F 5′- AGACCCGCCGAATGACCT -3′ 144
R 5′- GCACCAAACTGAGCAGAAGCG -3′
β-ACTIN F 5′- CTGGAACGGTGAAGGTGACA -3′ 140
R 5′- AAGGGACTTCCTGTAACAACGCA -3′Chromatin condensation analysis by Hoechst staining
After treatment with epigenetic modulators, cells were
stained with Hoechst 33342 stain (1 mg/mL, Invitrogen)
followed by incubation for 10 min at 37°C. Images were
taken under UV filter using Epi-fluorescent Microscope
(Olympus IX71) at 400 X magnification with an excitation
wavelength of 355 to 366 nm and an emission wavelength
of 465 to 480 nm. Condensed nuclei were counted against
total number of nuclei in the field, and the percentage of
apoptotic nuclei were calculated and plotted graphically.
Immunocytochemistry
Immunocytochemistry was performed as per our previous
protocol with some modifications [39-43]. In brief, MCF-7
and MDA-MB-231 cells were grown on glass coverslips
and treated with AZA (15 μM), SAM (15 μM), TSA (100
nM), and SFN (10 μM) for 24 h. The treated cells were
fixed by ice cold methanol and permeabilized by 0.25%
triton X-100 in PBS. Cells were incubated with 1% BSA
in PBST for 30 min to block non-specific binding of
the antibodies. The endogenous peroxidase activity was
blocked by incubating in 5% H2O2 in methanol for
20 min followed by incubation in primary antibodies
for DNMT1, DNMT3A, and DNMT3B overnight at
4°C. The cells were then washed in PBS and incubated
with HRP-conjugated anti-rabbit secondary antibody
(Santa Cruz Biotech) for 1 h followed by another wash.
Finally, reactions were visualized by incubation with 3,
3′-Diaminobenzidine (DAB, substrate and chromogen,
Sigma) and counterstained with Mayer’s hematoxylin.
For negative control, cells were incubated overnight
with dilution buffer (no primary antibody) [37].
Immunohistochemistry
Twenty formalin-fixed paraffin-embedded (FFPE) breast
tissue samples were collected from Drs. Tribedi & Roy
Diagnostic Laboratory (Kolkata, India). Of these samples,
two were cancer adjacent tissues whereas the rest of them
were cancerous tissues. Of the eighteen tumor tissues, ten
were primary stage and eight were metastatic stage breast
tissues. FFPE blocks were sliced into 0.5 μM thin slices
and subjected to antigen retrieval with tris-EDTA buffer,
endogenous peroxidase blocking, and rinsed with tris-
buffered saline (TBS) containing 0.025% Triton X-100
(TBS-T). Rabbit polyclonal anti-DNMT1 (Santa Cruz),
rabbit polyclonal anti-DNMT3A (Santa Cruz), rabbit poly-
clonal anti-DNMT3B (Santa Cruz), and rabbit polyclonal
anti-DNMT3B (Santa Cruz) were used as primary anti-
bodies. The secondary antibody used was anti-rabbit (Invi-
trogen). After incubation with primary antibodies at
4°C overnight, the specimens were rinsed with TBS and
incubated at room temperature for 1 h with secondary
antibody. After rinsing with TBS, all specimens were
color-developed with DAB.
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Flow cytometry analysis of Propidium Iodide (PI) stained
nuclei was done to assess the effect of epigenetic drugs on
the cell cycle distribution. AZA (15 μM), SAM (15 μM),
TSA (100 nM), and SFN (10 μM) treated cells were incu-
bated in respective media with 5% FBS for 24 h. The cells
were then trypsinized, collected by centrifugation (500 × g
for 5 mins at 4°C), washed twice with PBS and then fixed
in 90% ice-cold methanol. After incubation at -20°C for
1 h, cells were centrifuged and resuspended in PBS followed
by treatment with RNaseA (500 U/mL) to digest the residual
RNAs and stained with PI (10 μg/mL). Samples were incu-
bated for 30 min at 4°C and cell cycle analysis was per-
formed with a Becton-Dickinson fluorescence-activated cell
sorter (FACS).
Statistical analysis
All data are presented as means ± SD. Statistical analysis
was performed using the Student’s t-test by SPSS software.
Values of P <0.05 were considered as significant value.
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